【レポートの概要（一部）】
1. Report Overview
1.1 Multiple Sclerosis Drugs Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Multiple Sclerosis
2.1 What is Multiple Sclerosis?
2.1.1 Key Statistics: 2.5 Million Sufferers in the World
2.2 The Pathology of MS
2.2.1 Symptoms
2.3 Diagnosis of MS
2.3.1 Tests for MS Include These Technologies
2.4 Measuring MS
2.5 The Different Types of MS
2.5.1 Relapsing-Remitting MS (RRMS)
2.5.2 Secondary Progressive MS
2.5.3 Progressive Relapsing MS
2.5.4 Primary Progressive MS
2.5.5 Other Presentations of the Disease
2.6 Possible Causational Factors for MS
2.6.1 Genetic Factors
2.6.2 Infection
2.6.3 Environmental Factors and Less Well-Supported Theories
2.7 Demographics and Geographical Distribution
2.8 Different Treatments for MS
3. Leading Multiple Sclerosis Drugs
3.1 Copaxone (glatiramer acetate) by Teva Pharmaceutical Industries
3.1.1 First Non-Interferon Immunomodulator
3.1.2 Teva and the Approval of Generic Competition
3.1.3 The First Generic is Approved – Sandoz’s Glatopa
3.1.4 Industry Surprised by Copaxone’s Solid Sales, Despite Generic Competition: 40mg Dose is Key
3.1.5 Patents on Copaxone 40mg Being Contested – Although Teva Receives Good News in Europe
3.1.6 Copaxone Revenues 2011-2015
3.1.7 Copaxone Revenue Forecast 2016-2026
3.2 Tecfidera (dimethyl fumarate) by Biogen
3.2.1 Rapidly Grown Since 2013 to Become the Leading Oral MS Therapy
3.2.2 Tecfidera Revenues 2013-2015
3.2.3 Tecfidera Revenue Forecast 2016-2026
3.3 Avonex (interferon beta-1a) by Biogen
3.3.1 The Leading Interferon Therapy
3.3.2 Avonex Revenues 2011-2015
3.3.3 Patent Extension to 2026
3.3.4 Avonex Revenue Forecast 2016-2026
3.4 Gilenya (fingolimod) by Novartis
3.4.1 The First Oral Disease-Modifying Drug for MS
3.4.2 US Patent Trial and Appeal Board Sides Against Novartis
3.4.3 Gilenya Revenues 2011-2015
3.4.4 Gilenya Revenue Forecast 2016-2026
3.5 Rebif (interferon beta-1a) by Merck KGaA
3.5.1 Merck Attempting to Differentiate Rebif from Other Interferon Therapies
3.5.2 Rebif Revenues 2011-2015
3.5.3 Rebif Revenue Forecast 2016-2026
3.6 Tysabri (natalizumab) by Biogen
3.6.1 High Efficacy Offsets the Risks
3.6.2 Tysabri Revenues 2011-2015
3.6.3 Tysabri Revenue Forecast 2016-2026
3.7 Betaseron / Betaferon (interferon beta-1b) by Bayer
3.7.1 First Disease Modifying Drug for MS
3.7.2 Betaseron Revenues 2011-2015
3.7.3 Betaseron Revenue Forecast 2016-2026
3.8 Aubagio (teriflunomide) by Sanofi
3.8.1 More than 48,000 Patients Treated
3.8.2 Aubagio Revenues 2014-Q1 2016
3.8.3 Aubagio Revenue Forecast 2016-2026
3.9 Plegridy (peginterferon beta-1a) by Biogen
3.9.1 36% Reduction in ARR compared to Placebo
3.9.2 Plegridy Revenues 2014-2015
3.9.3 Plegridy Revenue Forecast 2016-2026
3.10 Lemtrada (alemtuzumab) by Sanofi
3.10.1 Very Effective, but with Side Effects
3.10.2 Lemtrada Past Revenues and Revenue Forecast 2016-2026
4. Multiple Sclerosis Drugs Pipeline 2016-2026
4.1 Ocrelizumab (Ocrevus / RG1594) by Roche
4.1.1 Humanised mAb Targeting CD20
4.1.2 First Drug to Receive Breakthrough Therapy Designation for MS
4.1.3 Exciting Latest Results from Two Phase 3 Trials
4.1.4 Ongoing Clinical Trials
4.1.5 Ocrelizumab Revenue Forecast 2016-2026
4.2 Ozanimod by Celgene
4.2.1 S1PR Modulator
4.2.2 Promising Results from Phase 2 RADIANCE Study
4.2.3 Ongoing Clinical Trials
4.2.4 Ozanimod in MS Revenue Forecast 2018-2026
4.3 Zinbryta (daclizumab high-yield process) by Biogen and AbbVie
4.3.1 Humanised mAb Being Jointly Developed by two Giants
4.3.2 Positive Opinion on Marketing Authorisation from the CHMP
4.3.3 Zinbryta Revenue Forecast 2016-2026
4.4 Ofatumumab by Novartis
4.4.1 Novartis Acquires Full Remaining Rights in $1bn Agreement
4.4.2 Advantages and Disadvantages over Ocrelizumab
4.5 Ponesimod by Actelion
4.5.1 S1PR Modulator
4.5.2 Positive Earlier Results
4.6 Laquinimod by Teva and Active Biotech
4.6.1 Troubled Oral Immunomodulator
4.6.2 Turned Down for European Licence
4.7 MED1003 by MedDay
4.7.1 Unique Method of Action
4.7.2 Results from MS-SPI and MS-ON
4.8 Masitinib by AB Science: Phase 3 and has Completed a Futility Analysis
4.9 Siponimod (BAF312) by Novartis: Competitor for Gilenya
5. Global Multiple Sclerosis Drugs Market 2016-2026
5.1 Global Multiple Sclerosis Drugs Market Forecast 2016-2026
5.2 What Factors Will Drive Growth in the Global MS Drugs Market?
5.2.1 Growth of Existing Products, Reaching Peak Blockbuster Revenues before Patent Expiry
5.2.2 Exciting New Products Due to be Launched Within the Next Ten Years
5.2.3 Premium Prices, Accompanied by Price Increases
5.2.4 Prevalence and Incidence of Multiple Sclerosis is Increasing
5.2.5 Unmet Needs and Strategic Partnering
5.3 What Factors will Restrain Growth in the Global MS Drugs Market?
5.3.1 Multiple Patent Expiries on Leading Drugs will Lead to Generic and Biosimilar Competition
5.3.2 Declining Healthcare Budgets Could Lead to Cost Pressures
5.3.3 Crowded Marketplace
6. Leading Therapeutic Segments: Revenue Prospects, 2016-2026
6.1 The Main Therapeutic Segments within the MS Drugs Market, Forecast 2016-2026
6.2 Therapeutic Composition of the Market in 2015, 2020 and 2026
6.3 Monoclonal Antibodies Segment Forecast 2016-2026
6.4 S1PR Modulator Segment Forecast 2016-2026
6.5 Interferons Segment Forecast 2016-2026
6.6 Other Immunomodulators Segment Forecast 2016-2026
6.7 ‘Others’ Segment Forecast 2016-2026
7. National Markets for MS Drugs: Revenue Prospects, 2016-2026
7.1 Multiple Sclerosis Cases and Prevalence Values
7.2 Leading Regional Markets Forecast 2016-2026
7.2.1 Regional Composition of the Market in 2015, 2020 and 2026
7.3 US MS Drugs Market
7.3.1 Reasons why the US Market Dominates the MS Drugs Market to Such an Extent
7.3.2 Undergoing Some Changes
7.3.3 US MS Drugs Market Forecast 2016-2026
7.4 EU5 MS Drugs Market 2016-2026
7.4.1 Common Characteristics of all the EU5 Nations in Regards to MS Drugs and Drivers of Growth
7.4.2 German MS Drugs Market: Leading EU Market
7.4.2.1 German MS Drugs Market Forecast 2016-2026
7.4.3 French MS Drugs Market: Strong Healthcare System
7.4.3.1 French MS Drugs Market Forecast 2016-2026
7.4.4 UK MS Drugs Market
7.4.4.1 UK MS Drugs Market Forecast 2016-2026
7.4.5 Italian MS Drugs Market
7.4.5.1 Italian MS Drugs Market Forecast 2016-2026
7.4.6 Spanish MS Drugs Market
7.4.6.1 Spanish MS Drugs Market Forecast 2016-2026
7.5 Canadian MS Drugs Market: Country has Highest Rate of MS in the World
7.5.1 Canadian MS Drugs Market Forecast 2016-2026
7.6 Japanese MS Drugs Market Forecast 2016-2026
7.7 Chinese MS Drugs Market Forecast 2016-2026
7.8 Indian MS Drugs Market Forecast 2016-2026
8. Conclusions from Our Research and Analysis
8.1 How will Revenues Change over the Forecast Period?
8.2 How will the Therapeutic Composition of the Market Change?
8.3 How will National Markets Develop from 2016 to 2026?
8.4 Concluding Remarks
【レポート販売概要】
■ タイトル：多発性硬化症治療薬の世界市場および研究開発展望2016-2026■ 英文：Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026
■ 発行日：2016年6月
■ 調査会社：visiongain
■ 商品コード：VGAIN60619
■ 調査対象地域：グローバル
- ギリシャの発電市場2016：市場動向、制度、競争状況Greece Power Market Outlook to 2030, Update 2016 - Market Trends, Regulations, and Competitive Landscape Summary This report elaborates Greece's power market structure and provides historical and forecast numbers for generation, capacity and consumption up to 2030. Detailed analysis of the Greece power market’s regulatory structure, import and export trends, competitive landscape, and power projec …
- アメリカのコネクテッドカーM2M通信およびサービス市場About the Connected Car M2M Connections and Services Market in US The connected car market has been fueled by factors such as rising demand for constant connectivity, increased dependency on technology, and the growing number of tech-savvy customers. Over the years, automotive manufacturers and service providers have been developing connectivity solutions such as M2M connectivity platforms. M2M co …
- IAM（アイデンティティー及びアクセス管理）ソリューションの世界市場：プロビジョニング、ディレクトリ技術、シングルサインオン(SSO)、認証Identity and access management can be defined as the management of entire lifecycle of digital identities, their authentication, authorization and audit. Today is an era of extended enterprise, where organizations are becoming more and more globalized day by day, this trend along with the need to maintain real time secure connectivity across an organization and its stakeholders will create an addi …
- アジア太平洋の学校用評価ツール市場2016-2020About the School Assessment Tools Market in APAC The education industry is transforming from the traditional classroom-based teaching to online education. The technology landscape in the school education sector is observing dynamic changes with regards to online education delivery methods, such as very small aperture terminal, 4G, and web conferencing. For education technology solutions, APAC is c …
- 飲料パッケージ（包装資材）の世界市場：種類別（ボトル、缶、ポーチ、カートン等）、材料別（ガラス、プラスチック、金属、板紙等）分析Beverage manufacturers have witnessed tremendous growth in the last five years. This has influenced the beverage packaging industry substantially and an upsurge was recorded in this industry simultaneously. New technologies have initiated the emergence of innovative packaging designs, but stringent regulations challenged the beverage packaging manufactures to prioritize environment health. Develop …
- 世界のコネクテッドカーM2M接続及びサービス市場：M2MGlobal Connected Car M2M Connections and Services Market 2014-2018TechNavio's analysts forecast the Global Connected Car M2M Connections and Services market to grow at a CAGR of 28.45 percent over the period 2014-2018. One of the key factors contributing to this market growth is the increasing awareness and demand for safety and security of connected car M2M services. The Global Connected Car M2M Connections & Services market has also been witnessing the launch …
- BRIC（ブラジル/ロシア/インド/中国）の腎盂形成処置動向（～2020）BRIC Pyeloplasty Procedures Outlook to 2020 Summary GlobalData’s new report, "BRIC Pyeloplasty Procedures Outlook to 2020", provides key market data on the BRIC Pyeloplasty Procedures. The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology based models to estimate and forecast the procedure volumes. The objective is to provide information that represent …
- クラウド上の拡張現実（Augmented Reality in the Cloud）Augmented Reality (AR) represents a live, direct or indirect, view of a physical, real-world environment whose elements are augmented by computer-generated sensory input, that enrich the user's perception of the real world. AR applications combine virtual data into the physical real world by utilizing the wireless devices, compass, camera, and GPS system. AR represents a potential large opportunit …
- 世界のエアフィルター市場動向：Global Air Filter Market 2014-2018TechNavio's analysts forecast the Global Air Filter market to grow at a CAGR of 4.95 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing demand from the APAC region. The Global Air Filter market has also been witnessing the increase in partnerships. However, the threat of rivalry could pose a challenge to the growth of this market. TechNav …
- データディスカバリの世界市場予測（～2021）：種類別、サービス別、用途別（リスク管理、販売＆マーケティング最適化、コスト最適化）、導入別、企業規模別、産業別、地域別Data discovery can be defined as a decision-making platform which assimilates, structures, and refines data. Globally, data discovery software and services are rapidly taking over from traditional Business Intelligence (BI) tools, which cannot be utilized and accessed without help from the technical staff. Major drivers of the data discovery market are rising trends of self-service BI tools and ge …
- 世界の食品のカプセル化市場動向及び予測（～2018）The primary factor driving the growth of the food encapsulation market is the rise in demand for functional foods which offer intended health benefits. This report estimates the market size of the food encapsulation market in terms of value. Bakery & confectionery, dairy & frozen desserts, convenience foods, functional foods, beverages, and meat, poultry & seafood are the key applications for enca …
- 実験室備品の世界市場：ラベルプリンター、ピペットチップ、マイクロプレート、試薬リザーバー、バルブ、チューブ、洗浄ステーションThe dearth of qualified laboratory professionals (over 17% of laboratory professionals are set to retire in the next five years) and rising aging population have increased the demand for laboratory automation. The application of advanced technology in testing laboratories has gained importance as it ensures timely progress and efficiency with minimal errors. This has led to the adoption of lab aut …
- 動物用非遺伝子組み換え飼料の世界市場2017-2021ABSTRACTAbout Non-GMO Animal Feed The global animal feed market is expected to grow at a stable pace during the forecast period. The increasing awareness of the health benefits of animal feed is driving this market. Also, the increased per capita consumption of meat at a global scale, mostly because of the increase in the overall population, is contributing to the demand for animal feed. The marke …
- 指紋センサーの世界市場予測（～2023年）“The fingerprint sensor market is expected to grow at a CAGR of 15.66% between 2018 and 2023” The fingerprint sensor market is expected to grow from USD 4.25 billion in 2018 to USD 8.80 billion by 2023 at a CAGR of 15.66%. The growth of this market is mainly driven by factors such as the proliferation of fingerprint sensors in smartphones and other consumer electronics, government support for the …
- 世界の湿潤創傷治療ドレッシング材市場2015The Global Moist Wound Dressings Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Moist Wound Dressings industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Moist Wound Dressings market analysis is provided for the international markets including deve …
